GlassScriptPhysician profile
Brenda C Olmos
NPI 1811410392
$12,149.31
in general payments reported to CMS, 2019-2025
43 companies · $3,114 in 2025
The $3,114 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,328 · 2022: $2,586 · 2023: $2,133 · 2024: $1,988 · 2025: $3,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,255 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $963 · Travel and Lodging: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,254.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $962.50 |
| Travel and Lodging | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,274.02 | 2021-2025 | Airsupra, Flumist Quadrivalent |
| Corcept Therapeutics | $1,438.89 | 2023-2025 | Korlym |
| Genzyme Corporation | $892.58 | 2024-2025 | |
| Gilead Sciences, INC. | $696.63 | 2022-2025 | Descovy, Livdelzi, Epclusa |
| Inspire Medical Systems, INC. | $644.39 | 2021-2025 | Inspire |
| Abbott Laboratories | $588.48 | 2022-2024 | Freestyle Libre 3, Proclaim, Eterna |
| Glaxosmithkline, LLC. | $568.49 | 2021-2022 | |
| Amgen INC. | $467.87 | 2022-2025 | Repatha, Repatha |
| Genentech USA, INC. | $361.92 | 2021-2022 | |
| Genentech, INC. | $349.16 | 2021-2023 | Xofluza, Xolair |
| Teva Pharmaceuticals USA, INC. | $334.46 | 2021-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $302.00 | 2023 | Gammagard, Takhzyro, Cuvitru |
| Abbvie INC. | $291.82 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $230.32 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $217.37 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $154.31 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $124.72 | 2022 | |
| Boston Scientific Corporation | $124.17 | 2025 | Watchman Flx |
| Neurocrine Biosciences, INC. | $123.38 | 2022 | |
| Viiv Healthcare Company | $121.86 | 2023 | Apretude |
| Stemline Therapeutics INC. | $121.84 | 2021 | |
| Theratechnologies INC. | $118.63 | 2021 | |
| Scynexis, INC. | $116.15 | 2022 | |
| Kyowa Kirin, INC. | $115.36 | 2023 | |
| Acadia Pharmaceuticals INC | $114.95 | 2021 | |
| Sandoz INC. | $112.43 | 2025 | |
| Penumbra, INC. | $111.62 | 2023 | Indigo System |
| Janssen Pharmaceuticals, INC | $110.65 | 2023 | Spravato |
| Amarin Pharma, INC. | $102.60 | 2025 | Vascepa |
| Astellas Pharma US INC | $96.96 | 2023 | Veozah |
| Bridgebio Pharma, INC. | $94.39 | 2025 | Attruby |
| Shield Therapeutics INC | $90.56 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $88.49 | 2022 | |
| Horizon Therapeutics Plc | $86.94 | 2022 | |
| Teleflex LLC | $84.28 | 2025 | Barrigel |
| Ethicon US, LLC | $81.18 | 2022 | |
| Shockwave Medical, INC | $49.22 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $38.49 | 2022 | |
| Organon LLC | $24.97 | 2024 | |
| Irhythm Technologies, INC. | $23.78 | 2024 | Zio Xt Patch, Zio Monitor |
| Dexcom, INC. | $22.14 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $20.41 | 2024 | Cologuard Collection Kit |
| Medtronic, INC. | $16.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Olmos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.